{"id":"https://openalex.org/W2385686208","doi":null,"title":"Cost-effectiveness Analysis of Two Therapeutic Schemes by Fenofibrate for Hyperlipidemia","display_name":"Cost-effectiveness Analysis of Two Therapeutic Schemes by Fenofibrate for Hyperlipidemia","publication_year":2012,"publication_date":"2012-01-01","ids":{"openalex":"https://openalex.org/W2385686208","mag":"2385686208"},"language":"en","primary_location":{"id":"mag:2385686208","doi":null,"is_oa":false,"landing_page_url":"https://en.cnki.com.cn/Article_en/CJFDTOTAL-HAIX201202138.htm","pdf_url":null,"source":{"id":"https://openalex.org/S2764714403","display_name":"Strait Pharmaceutical Journal","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4323972571","host_organization_name":"Strait Pharmacy Editorial Department","host_organization_lineage":["https://openalex.org/P4323972571"],"host_organization_lineage_names":["Strait Pharmacy Editorial Department"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Strait Pharmaceutical Journal","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101426552","display_name":"Meili Chen","orcid":"https://orcid.org/0000-0001-9784-5912","observed_orcids":["https://orcid.org/0000-0001-9784-5912"]},"institutions":[{"id":"https://openalex.org/I4210160695","display_name":"Shaoxing People's Hospital","ror":"https://ror.org/05v58y004","country_code":"CN","type":"healthcare","lineage":["https://openalex.org/I4210160695"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Meili Chen","raw_affiliation_strings":["Shaoxing people's hospital,Shaoxing 312000,China)"],"raw_orcid":"https://orcid.org/0000-0001-9784-5912","affiliations":[{"raw_affiliation_string":"Shaoxing people's hospital,Shaoxing 312000,China)","institution_ids":["https://openalex.org/I4210160695"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5101426552"],"corresponding_institution_ids":["https://openalex.org/I4210160695"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.36848776,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.7968999743461609,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.7968999743461609,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.19380000233650208,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.001500000013038516,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/fenofibrate","display_name":"fenofibrate","score":0.9990000128746033},{"id":"https://openalex.org/keywords/hyperlipidemia","display_name":"hyperlipidemia","score":0.9610000252723694},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.8270000219345093},{"id":"https://openalex.org/keywords/sustained-release-capsules","display_name":"sustained-release capsules","score":0.7990000247955322},{"id":"https://openalex.org/keywords/tablets","display_name":"tablets","score":0.5070000290870667},{"id":"https://openalex.org/keywords/drug-formulation-comparison","display_name":"drug formulation comparison","score":0.6209999918937683},{"id":"https://openalex.org/keywords/treatment-effectiveness","display_name":"treatment effectiveness","score":0.3930000066757202},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.8579999804496765}],"concepts":[{"id":"https://openalex.org/C2778110834","wikidata":"https://www.wikidata.org/wiki/Q419724","display_name":"Fenofibrate","level":2,"score":0.9964348077774048},{"id":"https://openalex.org/C2779091943","wikidata":"https://www.wikidata.org/wiki/Q1079120","display_name":"Hyperlipidemia","level":3,"score":0.8579059839248657},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6401711106300354},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.32895350456237793},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.32610565423965454},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.1135869026184082},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2385686208","doi":null,"is_oa":false,"landing_page_url":"https://en.cnki.com.cn/Article_en/CJFDTOTAL-HAIX201202138.htm","pdf_url":null,"source":{"id":"https://openalex.org/S2764714403","display_name":"Strait Pharmaceutical Journal","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4323972571","host_organization_name":"Strait Pharmacy Editorial Department","host_organization_lineage":["https://openalex.org/P4323972571"],"host_organization_lineage_names":["Strait Pharmacy Editorial Department"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Strait Pharmaceutical Journal","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2369140294","https://openalex.org/W2073396339","https://openalex.org/W7204056418","https://openalex.org/W2158099924","https://openalex.org/W2353078578","https://openalex.org/W1997674238","https://openalex.org/W4239562721","https://openalex.org/W2385956122","https://openalex.org/W2375609230","https://openalex.org/W7095644530"],"abstract_inverted_index":{"OBJECTIVE":[0],"To":[1],"evaluate":[2],"the":[3,39,95],"economic":[4],"efficiency":[5],"of":[6,16,74],"Fenofibrate":[7,10,31,45,48,76,85,88],"tablets":[8,28,46,89],"and":[9,30,47,55,63,69],"sustained":[11,32,49,77],"release":[12,33,50,78],"capsules":[13,34,79],"in":[14],"treatment":[15],"hyperlipidemia.METHODS":[17],"100":[18],"out-patients":[19],"clinic":[20],"with":[21],"hyperlipidemia":[22,93],"were":[23,53,61,67,80],"divided":[24],"into":[25],"two":[26,96],"groups:Fenofibrate":[27],"group":[29],"group.Data":[35],"was":[36],"evaluated":[37],"using":[38],"pharmacoeconimic":[40],"cost-effectiveness":[41,65,72],"analysis.RESULTS":[42],"For":[43],"Group":[44,75,84,87],"capsules,the":[51],"costs":[52],"220.7":[54],"329.6":[56],"yuan,respectively;the":[57],"total":[58],"effective":[59],"rates":[60],"88%":[62],"94%,respectively;the":[64],"ratios":[66,73],"250.8":[68],"350.6,respectively.The":[70],"incremental":[71],"1815":[81],"as":[82],"against":[83],"tablets.CONCLUSION":[86],"is":[90],"preferable":[91],"for":[92],"between":[94],"groups.":[97]},"counts_by_year":[],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2016-06-24T00:00:00"}